Nelly M Malenkovich

US Patent:

7038013, May 2, 2006

Filed:

Nov 2, 2001

Appl. No.:

10/002775

Inventors:

Gordon Freeman - Brookline MA, US
Vassiliki Boussiotis - Brookline MA, US
Tatyana Chernova - Brighton MA, US
Nelly Malenkovich - Boston MA, US

Assignee:

Dana-Faber Cancer Institute, Inc. - Boston MA

International Classification:

C07K 14/47
C07K 14/725
C07K 16/46
A61K 38/17
A61K 39/395

US Classification:

530350, 530351, 5303873, 514 12, 514 21, 4241341

Abstract:

The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7432059, Oct 7, 2008

Filed:

Jun 28, 2001

Appl. No.:

09/895837

Inventors:

Gordon Freeman - Brookline MA, US
Irene Chernova - Brighton MA, US
Tatyana Chernova - Mobile AL, US
Nelly Malenkovich - Boston MA, US
Clive Wood - Boston MA, US
Yvette Latchman - Brookline MA, US
Arlene H. Sharpe - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA
Genetics Institute, LLC - Cambridge MA
Brigham and Women's Hospital - Boston MA

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

US Patent:

7635757, Dec 22, 2009

Filed:

Jan 26, 2006

Appl. No.:

11/340429

Inventors:

Gordon Freeman - Brookline MA, US
Vassiliki Boussiotis - Brookline MA, US
Tatyana Chernova - Brighton MA, US
Nelly Malenkovich - Boston MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C07K 16/00
C07K 16/28
A61K 39/395
C12N 5/10
G01N 33/53

US Classification:

5303871, 5303873, 5303879, 5303881, 53038815, 53038822, 4241301, 4241331, 4241351, 4241361, 4241391, 435 71, 435 7021

Abstract:

The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7709214, May 4, 2010

Filed:

Jun 20, 2007

Appl. No.:

11/765838

Inventors:

Gordon J. Freeman - Brookline MA, US
Irene Chernova - Brighton MA, US
Tatyana Chernova - Brighton MA, US
Nelly Malenkovich - Boston MA, US
Clive R. Wood - Boston MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA
Genetics Institute, LLC - Cambridge MA

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

US Patent:

20020164600, Nov 7, 2002

Filed:

Jun 28, 2001

Appl. No.:

09/896913

Inventors:

Gordon Freeman - Brookline MA, US
Irene Chernova - Brighton MA, US
Tatyana Chernova - Mobile AL, US
Nelly Malenkovich - Boston MA, US
Clive Wood - Boston MA, US

International Classification:

C12Q001/68
C07H021/04
C12N009/16
C12P021/02
C12N005/06

US Classification:

435/006000, 435/183000, 435/196000, 435/069100, 435/320100, 435/325000, 536/023200

Abstract:

The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

US Patent:

6936704, Aug 30, 2005

Filed:

Aug 23, 2000

Appl. No.:

09/644934

Inventors:

Gordon Freeman - Brookline MA, US
Vassiliki Boussiotis - Brookline MA, US
Tatyana Chernova - Brighton MA, US
Nelly Malenkovich - Boston MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C07H021/04
C12P021/02
C12N005/10
C12N015/87
C12N015/63

US Classification:

536 235, 536 231, 536 234, 435 691, 435455, 4352523, 4353201, 435471, 435326

Abstract:

The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.